A gestational profile of placental exosomes in maternal plasma and their effects on endothelial cell migration.

Salomon C, Torres MJ, Kobayashi M, Scholz-Romero K, Sobrevia L, Dobierzewska A, Illanes SE, Mitchell MD, Rice GE. · 2014

Read A gestational profile of placental exosomes in maternal plasma and their effects on endothelial cell migration. by Salomon C, Torres MJ, Kobayashi M, Scholz-Romero K, Sobrevia L, Dobierzewska A, Illanes SE, Mitchell MD, Rice GE. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4048215.txt.

Introduction

Carlos Salomon and nine colleagues chart how placenta-shed vesicles in a mother's blood change across pregnancy, in PLoS ONE in 2014. Cells release exosomes, tiny parcels that carry messages between tissues. The placenta adds its own to maternal blood, where they may help tune blood vessels for the growing fetus.

Blood came from non-pregnant women and from women in each trimester, twenty per group. Vesicle counts ran more than fifty times higher in pregnancy. They rose further as pregnancy advanced, more than doubling by the third trimester. The placenta-marked share was tracked with a specific surface protein. In lab tests the vesicles sped the movement of vessel-lining cells, a step in vessel growth. The push was strongest for first-trimester vesicles and faded later. The authors offer the profile as a baseline. Departures from it might one day flag placental trouble early.

Catalog record

CREATORSalomon C, Torres MJ, Kobayashi M, Scholz-Romero K, Sobrevia L, Dobierzewska A, Illanes SE, Mitchell MD, Rice GE.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4048215

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Gestational Profile of Placental Exosomes in Maternal Plasma and Their Effects on Endothelial Cell Migration By Carlos Salomon, Maria Jose Torres, Miharu Kobayashi, Katherin Scholz-Romero, Luis Sobrevia, Aneta Dobierzewska, Sebastian E Illanes, Murray D Mitchell, Gregory E Rice, Cees Oudejans Published in: PLoS ONE DOI: 10.1371/journal.pone.0098667 ABSTRACT Abstract Studies completed to date provide persuasive evidence that placental cell-derived exosomes play a significant role in intercellular communication pathways that potentially contribute to placentation and development of materno-fetal vascular circulation. The aim of this study was to establish the gestational-age release profile and bioactivity of placental cell-derived exosome in maternal plasma. Plasma samples (n = 20 per pregnant group) were obtained from non-pregnant and pregnant women in the first (FT, 6–12 weeks), second (ST, 22–24 weeks) and third (TT, 32–38 weeks) trimester. The number of exosomes and placental exosome contribution were determined by quantifying immunoreactive exosomal CD63 and placenta-specific marker (PLAP), respectively. The effect of exosomes isolated from FT, ST and TT on endothelial cell migration were established using a real-time, live-cell imaging system (Incucyte). Exosome plasma concentration was more than 50-fold greater in pregnant women than in non-pregnant women (p<0.001). During normal healthy pregnancy, the number of exosomes present in maternal plasma increased significantly with gestational age by more that two-fold (p<0.001). Exosomes isolated from FT, ST and TT increased endothelial cell migration by 1.9±0.1, 1.6±0.2 and 1.3±0.1-fold, respectively compared to the control. Pregnancy is associated with a dramatic increase in the number of exosomes present in plasma and maternal plasma exosomes are bioactive. While the role of placental cell-derived exosome in regulating maternal and/or fetal vascular responses remains to be elucidated, changes in exosome profile may be of clinical utility in the diagnosis of placental dysfunction. INTRODUCTION The placenta plays a pivotal role in orchestrating maternal adaptation to pregnancy and synthesises and releases pregnancy-associated autacoids that influence fetal, placental and maternal metabolism [1]. In addition to soluble endocrine mediators, placental cells (including cytotrophoblasts, syncytiotrophoblast and placental mesenchymal stem cells) also release extracellular vesicles (ECVs – including: apoptotic bodies/vesicles (100–600 nm); shed microvilli (>400 nm); microvesicles (0.1–2 µm); and exosomes (30–100 nm)[2]) that may also modify maternal physiology and fetal development [3]. Indeed, over the past five years, our understanding of how cells communicate with each other, in health and disease, has undergone a paradigm shift with the recognition of the role of exosomes in inter-cellular signaling [4]. The role of placenta-derived exosomes in maternal adaptation to pregnancy remains to be established. Exosomes are cell-derived bioactive vesicles, secreted by exocytosis and reflect aspects of the physiological state and function of the originating cells, including the human placenta [5], [6]. In addition, the release and content of these nanovesicles can be affected by the extracellular micro-environment.[7]. Exosomes are characterised as spherical bilayer lipid vesicles of 30–100 nm diameter when imaged using cryosection electron microscopy. The exosomal lipid bilayer contains relatively high concentrations of cholesterol, sphingomyelin, ceramide and detergent resistant membrane domains (lipid rafts) making these vesicles extremely stable.[8]. Exosomes regulate intracellular pathways by sequestering signalling molecules from the cytoplasm by reducing their bioavailability or preventing their packaging and release via exocytosis.[9]. They contain mRNA, miRNA [10], cell-surface receptors [11] and protein mediators [12] that can interact with either adjacent or distal cells to reprogram their phenotype and regulate cell function [13]. Available data suggest that the release of exosomes represents an important and common mode of cell-to-cell communication [14] under both normal and pathological conditions [15], [16]. Previous studies have identified the presence of exosomal proteins released from first trimester and term placenta, including molecules with immunological functions such as HLA-G and B7 family immunomodulators [17]; soluble MHC class I chain-related protein A and B [18]; syncytin-1 expression [19]. Available data support a role for placenta-derived ECVs in immunosuppression and maintenance of the fetal allograft. Placenta-derived ECVs (including exosomes and microvesicles) have been identified in maternal plasma during normal pregnancy [20]–[22]. They contain placenta-specific proteins and miRNA, thus, may be differentiated from maternally-derived exosomes [23]–[25]. While the release of ECVs has been reported to change in association with complications of pregnancy, such as preeclampsia, the identity of ECV involved has yet to be unequivocally established and/or well characterised [21], [22], [26]–[28]. Studies completed to date provide persuasive evidence that placental cell-derived exosomes play a significant role in intercellular communication pathways that potentially contribute to placentation and development of maternal-fetal vascular exchange. Furthermore, the release and composition of these ECVs during normal pregnancies remain to be fully elucidated. We hypothesise that during normal, uncomplicated pregnancy the concentration of placenta-derived exosomes in maternal blood increases during pregnancy and correlates with uterine blood flow and placental weight at delivery. Furthermore, we suggest placenta-derived exosomes mediate maternal vascular adaptation to pregnancy. As such, the analysis of placenta-derived exosomes in maternal blood may represent a clinically useful, non-invasive test for placental function and/or dysfunction. The specific aims of this study were to establish pregnancy-associated changes in: the concentration, content and bioactivity of placenta-derived exosomes in maternal blood during pregnancy from normal healthy women. MATERIALS AND METHODS Study group and samples A time-series experimental design was used to established pregnancy-associated change in exosome concentration, content and bioactivity in maternal blood. Women were recruited, with informed, written consent, by research midwives from the Clinica Davila, Santiago, Chile. Serial blood samples (BD Vacutainer PLUS Tubes. EDTA) were collected from normal, healthy pregnant women (n = 20 women sampled three times during pregnancy) during first trimester (6–12 weeks), second trimester (22–24 weeks) and third trimester (32–38 weeks) of pregnancy. Human plasma samples were obtained in accordance with the Declaration of Helsinki and approved by the ethics committee of The University of Queensland.Tissue collection was approved by the Human Research Ethics Committees of the Royal Brisbane and Women's Hospital, and the University of Queensland (HREC/09/QRBW/14). Doppler ultrasound examinations of the umbilical artery (left and right arteries) were performed across the pregnancy (n = 49, 11 missing data values for pulsatility index across the pregnancy). Plasma samples were stored at −80°C until analysed (samples were not stored for more than three months). All experimental procedures were conducted within an ISO17025 accredited (National Association of Testing Authorities, Australia) research facility. All data were recorded within a 21 CRF part 11 compliant electronic laboratory notebook (Irisnote, Redwood City, CA, USA). Isolation of exosomes from maternal circulation Exosomes were isolated from plasma (1 ml) as previously described. [29] In brief, plasma was diluted with an equal volume of PBS (pH 7.4) and centrifuged at 2,000×g for 30 min at 4°C (Sorvall, high speed microcentrifuge, fixed rotor angle: 90°, Thermo Fisher Scientific Ins., Asheville, NC, USA,). The 2000 g supernatant fluid was then centrifuged at 12,000×g for 45 min at 4°C (Sorvall, high speed microcentrifuge, fixed rotor angle: 90°). The resultant supernatant fluid (2 ml) was transferred to an ultracentrifuge tube (Sorvall ultracentrifuge tubes) and centrifuged at 200,000×g for 75 min (Sorvall, T-8100, fixed angle ultracentrifuge rotor The pellet was suspended in PBS (30 ml) and filtered through a 0.22 µm filter (Steritop™, Millipore, Billerica, MA, USA) and then centrifuged at 200,000×g for 75 min. The 200,000 g pellet was resuspended in 2.5 M sucrose solution (4 ml) and added at the bottom of the ultracentrifuge

Read the complete text